Perceive Pharma

Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Pharmaceutical Therapeutics

$15M

Latest Funding

Series A

Latest Funding Stage

2025-02-18

Funding Date

$15M

Total Funding

17

Employees

United States

Location

San Francisco, California

City & State

Sales-Ready Summary

Perceive Bio recently raised a $15M Series A round, indicating new budget for growth. Their tech stack includes WordPress and other marketing tools, suggesting they could benefit from enhanced content management and marketing automation solutions.

Key Contacts
Unlock Contact Information

Upgrade to access founder details

Upgrade Now
Open Positions
View Careers Page
Hiring For
-
Unlock Tech Stack Data

Upgrade to access technology insights

Upgrade Now

Similar Startups

EvidenceHunt
EvidenceHunt Logo

EvidenceHunt is an AI-powered research assistant developed by medical professionals for healthcare research. Our focus is on delivering tools that streamline gathering and analyzing clinical evidence. With features like AI Chat for interactive queries and comprehensive Direct Search options, EvidenceHunt allows precise data retrieval andanalysis.

Ignota Labs
Ignota Labs Logo

Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions.

Monument Therapeutics
Monument Therapeutics Logo

Monument Therapeutics medical approach utilizes proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, enabling researchers to focus on the advancement of neuroscience drugs in areas of unmet medical needs.

EG 427
EG 427  Logo

EG 427 develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.